These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8359571)

  • 1. Somatostatin analogue therapy in functioning neuroendocrine gut tumors.
    Debas HT; Gittes G
    Digestion; 1993; 54 Suppl 1():68-71. PubMed ID: 8359571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
    Arnold R; Frank M; Kajdan U
    Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
    Gorden P; Comi RJ; Maton PN; Go VL
    Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
    Wynick D; Bloom SR
    J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
    Arnold R; Neuhaus C; Trautmann ME
    Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
    Stöckmann F; Creutzfeldt W
    Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
    Pasricha G; Padhi P; Daboul N; Monga DK
    Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor imaging of endocrine gastrointestinal tumors.
    Krenning EP; Kwekkeboom DJ; Oei HY; Reubi JC; van Hagen PM; Kooij PP; Reijs AE; Lamberts SW
    Schweiz Med Wochenschr; 1992 Apr; 122(17):634-7. PubMed ID: 1350377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.
    Saglam S; Hacisahinogullari H; Ozturk N; Kapran Y; Gulluoglu M; Turkmen C; Adalet I; Orhan Bilge A; Cem Balci N
    J BUON; 2015; 20(5):1201-5. PubMed ID: 26537065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide therapy for variceal hemorrhage.
    Cello JP; Chan MF
    Digestion; 1993; 54 Suppl 1():20-6. PubMed ID: 8103011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.
    Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R
    Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors.
    Maton PN
    Gastroenterol Clin North Am; 1989 Dec; 18(4):897-922. PubMed ID: 2559036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
    Khagi S; Saif MW
    JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide--a synthetic somatostatin.
    Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
    [No Abstract]   [Full Text] [Related]  

  • 20. Somatostatin and octreotide in the management of acute variceal hemorrhage.
    Avgerinos A; Armonis A; Raptis S
    Hepatogastroenterology; 1995 Apr; 42(2):145-50. PubMed ID: 7672763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.